Catheter Development for Epicardial Atrial Gene Painting
Award amount
$260,403Program and phase
STTR · Phase IAward year
2018Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- RITHIM BIOLOGICS INC.
- Proposal award date
- 2018-08-15
- Contract end date
- 2019-08-14
- UEI
- R8S7GFCEVKB3
- Solicitation number
- PAR17-036
- Topic code
- NCATS
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Novel Gene Therapy, Techniques, and Devices to Prevent Ventricular Tachycardia
- Novel Gene Therapy, Techniques, and Devices to Prevent Ventricular Tachycardia
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- A Novel Multi-Lineage Human Intestinal Organoid Screening Platform for Drug Discovery and Preclinical Testing
- A Novel Approach to Eliminate Length Impurities for High-Quality mRNA Production
- Development of CIL-0X: A Platform to Enhance Delivery of Inhaled RNA Therapeutics to Lung Cells
- Tethosomes: a non-viral DNA platform for durable expression of therapeutic transgenes in specific target cells
- Long-read sequencing-based diagnosis for complex genomic and DNA methylation changes
Research funding history
3 SBIR/STTR records share this UEI (2018–2025). Reported award amounts total $1,650,317. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services